vTv Therapeutics Inc. (VTVT) intrinsic value & 10-year financials
vTv Therapeutics Inc. (VTVT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 6.1% a year to $0, with an average return on invested capital of 61.1%.
- Graham intrinsic value
- —
- Share price (Oct 27, 2026)
- $25.81
- Revenue (FY2025)
- $0
- Revenue growth (10-yr CAGR)
- 6.1%
- ROIC (10-yr avg)
- 61.1%
- Free cash flow (FY2025)
- —
VTVT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$27.0M | — | — | — | 133.7% |
| FY2024 | $1.0M | -$18.5M | — | -$25.3M | -2377.6% | 82.7% |
| FY2023 | $0 | -$20.2M | — | -$19.1M | — | 90.3% |
| FY2022 | $2.0M | -$19.2M | — | -$16.0M | -1116.9% | 100.3% |
| FY2021 | $4.0M | -$13.0M | — | -$19.3M | -540.9% | 40.3% |
| FY2020 | $6.4M | -$8.5M | — | -$18.0M | -184.8% | 18.3% |
| FY2019 | $2.8M | -$13.0M | — | -$23.1M | -755.9% | 36.7% |
| FY2018 | $12.4M | -$7.9M | — | -$26.9M | -159.4% | 28.6% |
| FY2017 | $291.0K | -$16.1M | — | -$44.6M | -17416.5% | 38.6% |
| FY2016 | $634.0K | -$16.4M | — | -$48.3M | -8678.2% | 41.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
vTv Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
vTv Therapeutics Inc. has earned high returns on invested capital, averaging 61.1% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
vTv Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, vTv Therapeutics Inc. is modeled at 6.1% normalized earnings growth with a 5.1% bond-yield adjustment.